Cibus Q2 2023 net loss $20.5M; reports business progress with trait transfers and Bayer collaboration

Cibus, Inc.

2023-Q2 EPS reported -$6.73 revenue$239,000

Net loss of $20.5M ($3.05 per share) vs $2.5M loss in prior-year quarter; cash $50.9M expected into Q1 2024.
Closed merger of Cibus Global and Calyxt on May 31, 2023; first trait transfers to Nuseed (canola pod shatter) and Nutrien (rice HT1/HT3) completed.
Opened 32,000 sq ft Oberlin facility in San Diego for semi-automated high-throughput gene editing trait production.
Entered collaboration with Bayer Ag to evaluate Cibus' Trait Machine platform for precision gene editing.
EU regulation proposal would treat Cibus' gene-edited traits as 'conventional-like', opening EU market if adopted.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Cibus, Inc. reported financial results for three months ended June 30, 2023.

Period: three months ended June 30, 2023
Result: reported results

Exact text from the filing

On August 9, 2023, Cibus, Inc. (the “Company”) announced its financial results for the three months ended June 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Cibus, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-028651

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.